Filtered By:
Condition: Headache
Management: Funding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Will unpredictable side effects dim the promise of new Alzheimer ’s drugs?
A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months. As many neurologists, patients, and brain scientists celebrate, they’re also nervously eyeing complications from treatment: brain swelling and bleeding, which in clinical trials affected up to about one-third of patients and ranged from asymptomatic to fatal.
The side effect—amyloid-related imaging abnormalities, or ARIA—remains mysterious. “We don’...
Source: Science of Aging Knowledge Environment - August 2, 2023 Category: Geriatrics Source Type: research
Seurat Therapeutics gets $500K for its migraine-fighting nasal spray
A Chicago-based medical startup that wants to stop migraines using a nasal spray received more funding this week to continue its research.
Seurat Therapeutics, a biotech startup founded within the University of Chicago, received a $500,000 grant from the National Institute of Neurological Disorders and Stroke.
The funding will help the startup continue testing its product, a nasal spray that aims to stop the cause of migraines. The funding comes after the company raised $750,000 in seed funding…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 19, 2018 Category: Pharmaceuticals Authors: Tatiana Walk-Morris Source Type: news
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial
Publication date: June 2018 Source:The Lancet Neurology, Volume 17, Issue 6 Author(s): Bum Joon Kim, Eun-Jae Lee, Sun U Kwon, Jong-Ho Park, Yong-Jae Kim, Keun-Sik Hong, Lawrence K S Wong, Sungwook Yu, Yang-Ha Hwang, Ji Sung Lee, Juneyoung Lee, Joung-Ho Rha, Sung Hyuk Heo, Sung Hwan Ahn, Woo-Keun Seo, Jong-Moo Park, Ju-Hun Lee, Jee-Hyun Kwon, Sung-Il Sohn, Jin-Man Jung, Jose C Navarro, Dong-Wha Kang Background The optimal treatment for patients with ischaemic stroke with a high risk of cerebral haemorrhage is unclear. We assessed the efficacy and safety of cilostazol versus aspirin, with and without probucol, in these pati...
Source: The Lancet Neurology - May 17, 2018 Category: Neurology Source Type: research
Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD
Dr. Ehlers is with Biogen in Cambridge, Massachusetts.
Innov Clin Neurosci. 2018;15(3–4):15–16
Funding: No funding was received for the preparation of this article.
Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts.
Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research
Letter to the Editor: Pneumocephalus: Is the needle size significant?
Discussion. Pneumocephalus is defined by two mechanisms: a ball-valve and an inverted bottle concept.1 The ball-valve type implies positive pressure events, such as coughing or valsalva maneuvers, that prevent air escape. Tension pneumocephalus is included in this mechanism, causing a parenchymal mass effect. The inverted bottle theory includes a negative intracranial pressure gradient following cerebrospinal fluid drainage, relieved by air influx. A small pneumocephalus is usually sealed by blood clots or granulation, allowing spontaneous reabsorption and resolution.[1] Otherwise, the lateral positioning of a patient duri...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Assessment Tools CNS Infections Current Issue Letters to the Editor Neurologic Systems and Symptoms Neurology Stroke Traumatic Brain Injury epidural needle size Pneumocephalus spinal tap Source Type: research
Global, regional, and national burden of neurological disorders during 1990 –2015: a systematic analysis for the Global Burden of Disease Study 2015
Publication date: Available online 17 September 2017 Source:The Lancet Neurology Author(s): GBD 2015 Neurological Disorders Collaborator GroupValery LFeiginAmanuel AlemuAbajobirKalkidan HassenAbateFoadAbd-AllahAbdishakur MAbdulleSemaw FeredeAberaGebre YitayihAbyuMuktar BeshirAhmedAmani NidhalAichourIbtihelAichourMiloud Taki EddineAichourRufus OlusolaAkinyemiSamerAlabedRajaaAl-RaddadiNelsonAlvis-GuzmanAzmeraw T.AmareHosseinAnsariPalwashaAnwariJohanÄrnlövHamidAsayeshSolomon WeldegebrealAsgedomTesfay MehariAteyLeticiaAvila-BurgosEuripideFrinelG. ArthurAvokpahoAleksandraBaracMiguelBarbozaSuzanne LBarker-ColloTillBärnighaus...
Source: The Lancet Neurology - September 19, 2017 Category: Neurology Source Type: research
Neurological Diseases Cost The U.S. $800 Billion Each Year
Over 100 million Americans ― close to a third of the total population ― suffer from neurological diseases such as Alzheimer’s, multiple sclerosis, migraines, epilepsy and spinal cord injury.
These conditions put an enormous financial strain on the health care system, totaling nearly $800 billion in annual costs, according to a new report published in the journal Annals of Neurology. To put that into perspective, the figure exceeds the U.S. military budget by over $100 billion.
That number reflects the total cost of the nine most common neurological diseases, but the total costs related to th...
Source: Healthy Living - The Huffington Post - March 30, 2017 Category: Consumer Health News Source Type: news
Hillary Clinton's New Platform Is A Blow To Mental Health Stigma
Democratic presidential nominee Hillary Clinton released a wide-ranging mental health plan on Monday, saying that her office would support Americans living with mental health issues through better legislation.
“The next generation must grow up knowing that mental health is a key component of overall health and there is no shame, stigma or barriers to seeking out care,” Clinton’s campaign stressed in an announcement.
Of course, candidate platforms rarely remain intact if they actually become policy after election day, but Clinton’s focus on normalizing mental health treatment reflects growi...
Source: Healthy Living - The Huffington Post - August 30, 2016 Category: Consumer Health News Source Type: news
ACR Preliminary Summary of Radiology Provisions in the 2017 MPFS Proposed Rule
The Centers for Medicare and Medicaid Services (CMS) released the Medicare Physician Fee Schedule (MPFS) proposed rule on Thursday, July 7. Upon initial review, the American College of Radiology (ACR) is pleased with several provisions within the rule. CMS has recognized the value provided by radiologists in providing mammography services through an increase in the physician work relative value units (RVUs) for diagnostic mammography and maintaining the current value for screening mammography. Additionally, ACR physicians and staff held numerous conference calls and meetings with CMS on the topic of appropriate use criteri...
Source: American College of Radiology - July 8, 2016 Category: Radiology Source Type: news
Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial
Publication date: Available online 12 February 2015 Source:The Lancet Neurology Background Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to reduce risk of stroke but whether one treatment strategy is more effective than the other is unknown. We compared their efficacy in the Cervical Artery Dissection in Stroke Study (CADISS), with the additional aim of establishing the true risk of recurrent stroke. Methods W...
Source: The Lancet Neurology - February 13, 2015 Category: Neurology Source Type: research
Quick magnesium treatment fails to improve stroke outcomes, but study has silver lining
In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of the onset of symptoms does not improve stroke outcomes.
However, the 8-year trial did find that with the help of paramedics in the field, intravenous medications can frequently be administered to stroke victims within that so-called "golden hour," during which they have the best chance to survive and avoid debilitating, long-term neurological damage.
The latter finding is a "game-changer," said Dr. Jeffrey Saver, director of the UCLA Stroke Center and a professor of ...
Source: UCLA Newsroom: Health Sciences - February 13, 2014 Category: Universities & Medical Training Source Type: news
Researchers ID more pesticides linked to Parkinson's, gene that increases risk
This report provides evidence for the relevance of ALDH inhibition in Parkinson's disease pathogenesis, identifies pesticides that should be avoided to reduce the risk of developing Parkinson's disease and suggests that therapies modulating ALDH enzyme activity or otherwise eliminating toxic aldehydes should be developed and tested to potentially reduce Parkinson's disease occurrence or slow its progression, particularly for patients exposed to pesticides," the study states.
The study was funded in part by the National Institute of Environmental Health Sciences (P01ES016732, R01ES010544, 5R21ES16446-2 and U54ES0120...
Source: UCLA Newsroom: Health Sciences - February 3, 2014 Category: Universities & Medical Training Source Type: news
Results of trial to determine how to prevent future strokes encouraging
UCLA RESEARCH ALERT
FINDINGS:
The results of a major, multicenter clinical trial to determine the best treatment for younger patients who have strokes that are potentially due to a hole in the upper chambers of the heart has provided suggestive but not definitive evidence of the benefit of a new heart hole–closure device.
The trial sought to determine which was the best treatment to prevent further strokes: a combination of closing the hole with a "button" device and anti-clotting medicines, or anti-clotting medicines alone. UCLA was one of the 69 performance sites for the study, called the Recurre...
Source: UCLA Newsroom: Health Sciences - March 20, 2013 Category: Universities & Medical Training Source Type: news
